Redeye comments on EG7’s Q2-results which came in weaker than expected, with somewhat lower revenue ...
Marimekko’s domestic sales proved more resilient in Q2 than we expected while international growth w...
Relais' Q2 adjusted EBITA came in well in line with LSEG Data & Analytics consensus expectations.
Redeye retains its positive view of Transtema following a Q2 report roughly matching our expectation...
- Earnings disappointment in Q2, but strong cash flow - We lower our US and Germany EBIT estimates -...
Voi, som är VNV Globals näst största innehav, kom med en mycket stark Q2-rapport.
Robust growth continued as expected, though profitability fell slightly short of our estimates due t...
Redeye retains its positive view of Transtema following a Q2 report that aligns with our expectation...
Redeye comments on Embracer’s Q1-results which were weaker than expected, owing mainly to soft perfo...
Redeye comments on the 350MW asset management agreement, spread over 94 turbines, that was signed tw...
Taaleri's Q2 results came largely in line with our expectations on an underlying basis, owing to goo...
EQL Pharma redovisade ökad nettoomsättning och EBIT i det första kvartalet.
50% y-o-y organic sales growth in Q2'25e EBIT forecasts raised by 1.
Q2'25e organic sales growth of 45% y-o-y We raise '25e paying users by 2% FVR of SEK 30-45 reiterate...
Taaleri’s continuing earnings of EUR 10.6m increased by 6% y/y and were 8% above our estimate.
